Structural dynamics of cisplatin binding to histidine in a protein

Structural Dynamics

Volumn 1, Issue 3, 2014, Pages

  Tanley, Simon W M ^a   Helliwell, John R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; GLASS TRANSITION; PLATINUM; PROTEINS; STRUCTURAL DYNAMICS; VIBRATION ANALYSIS;

ANTI-CANCER AGENTS; BINDING MODES; CARBOPLATIN; CISPLATIN BINDING; HEN EGG WHITE LYSOZYME; MEAN SQUARE DISPLACEMENT; MODEL PROTEINS; VIBRATION AMPLITUDE;

AMINO ACIDS;

EID: 84928148857     PISSN: None     EISSN: 23297778     Source Type: Journal    
DOI: 10.1063/1.4883975     Document Type: Article

References (34)

1. I.Kostova, "Platinum complexes as anticancer agents," Recent Pat. Anti-Cancer Drug Discovery 1, 1-22 (2006).
2. M.Benedetti, J. Malina, J. Kasparkova, V. Brabec, and G. Natile, "Chiral discrimination in platinum anticancer drugs," Environ. Health Perspect. 110, 779-782 (2002).
3. A.P. Silverman, W. Bu, S. M. Cohen, and S. J. Lippard, "2.4 A ° crystal structure of the asymmetric platinum complex {Pt(ammine)(cyclohexylamine)}2{thorn} bound to a dodecamer DNA duplex," J. Biol. Chem. 277, 49743-49749 (2002).
4. S.J. Fischer, L. M. Benson, A. Fauq, S. Naylor, and A. J. Windebank, "Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity," Neurotoxicology 29, 444-452 (2008).
5. O.Pinato, C. Musetti, and C. Sissi, "Pt-based drugs: The spotlight will be on proteins," Metallomics 6, 380-395 (2014).
6. F.Arnesano and G. Natile, "Platinum on the road: Interactions of antitumoral cisplatin with proteins," Pure Appl. Chem.80, 2715-2725 (2008).
7. S.E. Crider, R. J. Holbrook, and K. J. Franz, "Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1," Metallomics 2, 74-83 (2010).
8. A.Casini, C. Gabbiani, G. Mastrobuoni, L. Messori, G. Moneti, and G. Pieraccini, "Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome C," ChemMedChem 1, 413-417 (2006).
9. A.Casini, C. Gabbiani, G. Mastrobuoni, R. Z. Pellicani, F. P. Intini, F. Arnesano, G. Natile, G. Moneti, S. Francese, and L. Messori, "Insights into the molecular mechanisms of protein platination from a case study: The reaction of anticancer platinum(II) iminoethers with horse heart cytochrome C," Biochemistry 46, 12220-12230 (2007).
10. A.I. Ivanov, J. Christodoulou, J. A. Parkinson, K. J. Barnham, A. Tucker, J. Woodrow, and P. J. Sadler, "Cisplatin binding sites of human albumin," J. Biol. Chem. 273, 14721-14730 (1998).
11. C.G. Hartinger, W. H. Ang, A. Casini, L. Messori, B. K. Keppler, and P. J. Dyson, "Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI," J. Anal. At. Spectrom. 22, 960-967 (2007).
12. T.Zimmerman and J. V. Burda, "Cisplatin interaction with amino acids cysteine and methionine from gas phase to solutions with constant pH," Interdiscip. Sci.: Comput. Life Sci. 2, 98-114 (2010).
13. M.Huliciak, J. Vacek, M. Sebela, E. Orolinova, J. Znaleziona, M. Havlikova, and M. Kubala, "Covalent binding of cisplatin impairs the function of Na{thorn}/K{thorn}-ATPase by binding to its cytoplasmic part," Biochem. Pharmacol. 83, 1507-1513 (2012).
14. X.Wang, M. Cui, C. Zhao, L. He, D. Zhu, B. Wang, and W. Du, "Regulation of aggregation behavior and neurotoxicity of prion neuropeptides by platinum complexes," Inorg. Chem. 53, 5044-5054 (2014).
15. A.Casini, G. Mastrobuoni, C. Temperini, C. Gabbiani, S. Francese, G. Moneti, C. T. Supuran, A. Scozzafava, and L. Messori, "ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme," Chem. Commun. 14(2), 156-158 (2007).
16. S.W. M. Tanley, A. M. M. Schreurs, L. M. J. Kroon-Batenburg, J. Meredith, R. Prendergast, D. Walsh, P. Bryant, C. Levy, and J. R. Helliwell, "Structural studies of the effect that dimethyl sulfoxide (DMSO) has on cisplatin and carboplatin binding to histidine in a protein," Acta Crystallogr., Sect. D: Biol. Crystallogr. 68, 601 (2012).
17. S.W. M. Tanley, A. M. M. Schreurs, L. M. J. Kroon-Batenburg, and J. R. Helliwell, "Room-temperature X-ray diffraction studies of cisplatin and carboplatin binding to His15 of HEWL after prolonged chemical exposure," Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 68, 1300-1306 (2012).
18. J.R. Helliwell and S. W. M. Tanley, "The crystal structure analysis of the relative binding of cisplatin and carboplatin in a mixture with histidine in a protein studied at 100 and 300 K with repeated X-ray irradiation," Acta Crystallogr., Sect. D: Biol. Crystallogr. 69, 121-125 (2013).
19. S.W. M. Tanley, K. Diederichs, L. M. J. Kroon-Batenburg, A. M. M. Schreurs, and J. R. Helliwell, "Experiences with archived raw diffraction images data: capturing cisplatin after chemical conversion of carboplatin in high salt conditions for a protein crystal," J. Synchrotron Radiat. 20, 880-883 (2013).
20. S.W. M. Tanley and J. R. Helliwell, "Chemical conversion of cisplatin and carboplatin with histidine in a model protein crystallised under sodium iodide conditions," Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. (submitted).
21. S.W. M. Tanley, K. Diederichs, L. M. J. Kroon-Batenburg, C. Levy, A. M. M. Schreurs, and J. R. Helliwell, "Carboplatin binding to histidine," Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. (submitted).
22. J.Wang, M. Dauter, R. Alkire, A. Joachimiak, and Z. Dauter, "Triclinic lysozyme at 0.65 A resolution," Acta Crystallogr., Sect. D: Biol. Crystallogr. 63, 1254-1268 (2007).
23. C.Bon, M. S. Lehmann, and C. Wilkinson, "Quasi-laue neutron-diffraction study of the water arrangement in crystals of triclinic hen egg-white lysozyme," Acta Crystallogr., Sect. D: Biol. Crystallogr. 55, 978-987 (1999).
24. G.Zaccai, "Ecology of protein dynamics," Curr. Phys. Chem. 3, 9-16 (2011).
25. J.M. Finkelstein, "Protein dynamics: Shake it up, baby," Nat. Chem. Biol. 9, 600 (2013).
26. A.J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J. Read, "Phaser crystallographic software," J. Appl. Crystallogr. 40, 658-674 (2007).
27. A.Vagin and A. Teplyakov, "Molecular replacement with MOLREP," Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 22-25 (2010).
28. M.Cianci, J. R. Helliwell, and A. Suzuki, "The interdependence of wavelength, redundancy and dose in sulfur SAD experiments," Acta Crystallogr., Sect. D: Biol. Crystallogr. 64, 1196-1209 (2008).
29. P.Emsley and K. Cowtan, "Coot: Model-building tools for molecular graphics," Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132 (2004).
30. G.M. Sheldrick, "A short history of SHELX," Acta Crystallogr., Sect. A: Found. Crystallogr. 64, 112-122 (2008).
31. See supplementary material at http://dx.doi.org/10.1063/1.4883975 for the further, figure of cisplatin and carboplatin bound to the Nd and Ne atoms of His-15, the figure of cisplatin binding to the Nd and Ne atoms of His-15 as seen with the X-ray diffraction data at 200 K processed via XDS and a table of total X-ray absorbed Dose for each crystal.
32. S.W. M. Tanley, K. Diederichs, L. M. J. Kroon-Batenburg, A. M. M. Schreurs, and J. R. Helliwell, "Carboplatin binding to a model protein in non-NaCl conditions to eliminate partial conversion to cisplatin, and the use of different criteria to choose the resolution limit," arXiv:1309.4661 (2013).
33. W.Kabsch, "XDS," Acta Crystallogr., Sect. D: Biol. Crystallogr. 66, 125-132 (2010).
34. W.Doster, S. Cusack, and W. Petry, "Dynamical transition of myoglobin revealed by inelastic neutron scattering," Nature 337, 754-756 (1989).